Research progress on pharmacological mechanism and clinical application of Lokivetmab

Lokivetmab is a monoclonal antibody against canine derived interleukin-31 (IL-31), a novel targeted biological agent developed through hybridoma or recombinant DNA technology, aimed at specifically blocking the IL-31 mediated itch signaling pathway.

Recent Advances
Product Information

Recent Advances

I. Molecular Characteristics and Research Background of Lokivetmab

Lokivetmab is a monoclonal antibody targeting canine interleukin-31 (IL-31), belonging to a new class of targeted biological agents. It is developed through hybridoma technology or recombinant DNA technology by pharmaceutical companies, aiming to specifically block the pruritus signaling pathway mediated by IL-31. As the first monoclonal antibody approved by regulatory authorities for the treatment of canine allergic skin diseases, its development has filled the gap in targeted anti-pruritus therapy in veterinary medicine, providing a new option for precise treatment of pet skin diseases.

IL-31, secreted by activated T lymphocytes, mast cells, etc., is a key pro-inflammatory cytokine in allergic inflammation. Studies have found that it binds to the IL-31 receptor (IL-31RA) on the surface of cutaneous sensory nerve endings, activating downstream signaling pathways to trigger pruritus and skin inflammation. In dogs with allergic skin diseases, IL-31 levels are abnormally elevated and positively correlated with the severity of pruritus, which provides a solid theoretical basis for the targeted therapy of Lokivetmab. Its development is based on an in-depth understanding of the biological functions of IL-31, alleviating symptoms by specifically neutralizing IL-31 activity to block receptor interaction.

II. Molecular Structure and Mechanism of Action of Lokivetmab

(I) Molecular Structural Characteristics

Lokivetmab is an IgG-class monoclonal antibody, consisting of two heavy chains and two light chains connected by disulfide bonds to form a Y-shaped structure with a molecular weight of approximately 150 kDa. The three complementarity-determining regions (CDRs) in the variable region of the heavy chain are responsible for specifically recognizing and binding to IL-31 epitopes, which have extremely high specificity and affinity after directed evolution screening. Compared with traditional polyclonal antibodies, it has high homogeneity, and its antigen-binding site precisely matches the amino acid sequence of canine IL-31, avoiding cross-reaction with other cytokines.

Through protein engineering optimization, its half-life is significantly prolonged and bioavailability is improved, laying the foundation for long-acting treatment. The Fc segment has been modified to reduce binding ability to Fc receptors in the canine immune system, decreasing antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) effects, thereby enhancing medication safety.

(II) Mechanism of Action

The core function of Lokivetmab is to competitively bind to canine IL-31, preventing it from binding to the IL-31 receptor complex (IL-31RA/OSMRβ) and blocking downstream signal transduction. IL-31 receptors are mainly expressed on the surface of cutaneous sensory nerve cells, keratinocytes, and immune cells. After binding, they activate pathways such as JAK-STAT and MAPK, triggering neural excitation and release of inflammatory mediators, leading to pruritus and skin damage.

The binding of Lokivetmab to IL-31 has high specificity and affinity with a dissociation constant (Kd) at the nanomolar level, efficiently neutralizing free IL-31. In vitro experiments have shown that it can concentration-dependently inhibit IL-31-induced calcium influx in nerve cells and the release of inflammatory factors such as IL-6 and TNF-α. In skin tissue, it reduces IL-31-mediated neural sensitization to lower the excitability of pruriceptors, alleviating pruritus and scratching behavior in dogs, and indirectly reducing the risk of skin damage and secondary infection.

III. Pharmacokinetic Characteristics of Lokivetmab

(I) Absorption and Distribution

Lokivetmab is administered by subcutaneous injection and has good bioavailability in dogs, reaching peak plasma concentration (Cmax) 1-2 days after administration. The absorption rate is affected by factors such as injection site and subcutaneous fat thickness, but overall absorption is stable with small individual differences. Pharmacokinetic studies have shown that after a single subcutaneous injection of the recommended dose, the plasma concentration-time curve presents a one-compartment model with a half-life of approximately 1-2 weeks, significantly longer than traditional small-molecule drugs.

In terms of in vivo distribution, it mainly exists in blood and extracellular fluid and can reach skin tissue through the vascular endothelial barrier at inflammatory sites. Tissue distribution studies have shown that drug concentration in skin tissue after administration is significantly higher than in non-inflammatory tissue, which is related to increased vascular permeability at inflammatory sites and drug targeting aggregation mediated by highly expressed IL-31 antigen. The half-life of the drug in skin is slightly longer than in blood, facilitating sustained local anti-inflammatory and antipruritic effects.

(II) Metabolism and Excretion

As a protein drug, Lokivetmab has a metabolic pathway similar to endogenous antibodies, mainly being taken up by phagocytes through the reticuloendothelial system and decomposed into amino acids for reuse by the body. It is not metabolized through the hepatic cytochrome P450 enzyme system, resulting in few metabolic interactions with other drugs. Excretion mainly involves renal excretion of metabolites, with extremely low levels of the parent drug in urine.

Pharmacokinetic studies under special physiological conditions have shown that there are no significant changes in pharmacokinetic parameters in elderly dogs and dogs with mild hepatic or renal insufficiency, and no dose adjustment is needed. However, dogs with severe malnutrition or protein-losing diseases may affect drug distribution and elimination, requiring individualized adjustment of the administration plan.

IV. Clinical Application Scope of Lokivetmab

(I) Treatment of Allergic Skin Diseases

Lokivetmab is mainly used clinically to treat pruritus caused by canine allergic skin diseases, including atopic dermatitis, food allergies, flea allergic dermatitis, etc. Clinical trials have shown that pruritus in moderate to severe cases improves significantly 1-2 weeks after a single injection, with reduced scratching frequency and alleviated skin erythema and damage.

In the treatment of atopic dermatitis, it can be used as a long-term maintenance drug. When used in combination with glucocorticoids or immunosuppressants, it can reduce the dosage and adverse reactions of traditional drugs. Multicenter randomized controlled trials have shown that pruritus scores decrease by more than 50% 4 weeks after medication compared with the placebo group, with a 60%-70% improvement rate in skin lesions. The efficacy can last 4-8 weeks, reducing the frequency of administration. For dogs resistant or intolerant to glucocorticoids, it can be used as an alternative to improve safety.

(II) Other Potential Application Fields

In addition to allergic skin diseases, Lokivetmab shows potential value in other IL-31-related diseases. Studies have found that IL-31 is involved in otitis externa and perianal pruritus associated with canine atopic dermatitis, and preliminary observations have shown that it can relieve pruritus in these complications. In veterinary research, it has been used to explore the role of IL-31 in allergic diseases of other species such as cats and horses, providing reference for cross-species treatment.

Furthermore, its success provides insights for the treatment of human skin diseases. Since canine atopic dermatitis has similar pathogenesis to human atopic dermatitis, research on its mechanism of action helps deepen understanding of the role of IL-31 in human allergic diseases and promotes the development of human IL-31 monoclonal antibodies. Currently, drugs based on similar mechanisms have entered clinical trials for the treatment of atopic dermatitis and chronic spontaneous urticaria.

V. Safety and Adverse Reactions of Lokivetmab

A large amount of clinical research and post-marketing monitoring data have shown that Lokivetmab has good safety and tolerability. Compared with traditional glucocorticoids, the incidence of systemic adverse reactions is significantly lower, with the main being local injection site reactions, manifested as transient redness, pain, or itching, which usually resolve spontaneously within 24-48 hours without special treatment.

Long-term toxicity studies have shown no obvious organ toxicity after continuous administration for 6 months, with normal hematological and biochemical indicators. Due to its specific targeting of canine IL-31, it has little impact on other cytokines and immune system functions, does not increase infection risk, or interfere with vaccine efficacy. Reproductive toxicity studies have shown that the recommended dose has no adverse effects on canine reproductive function and fetal development and can be used in breeding dogs, but caution is still needed during pregnancy and lactation.

Despite good safety, a few adverse reactions may still occur. Systemic adverse reactions include mild lethargy and anorexia, with an incidence of less than 5%, which resolve spontaneously 1-3 days after administration. Allergic reactions occur very rarely, manifested as facial swelling, difficulty breathing, etc., requiring immediate discontinuation and administration of antihistamines or epinephrine. Approximately 1%-2% of dogs may produce anti-drug antibodies after long-term use, leading to decreased efficacy, and symptom recurrence usually occurs after 3-6 months of treatment, requiring a change of treatment plan. Moreover, it only relieves symptoms without curing the cause, so it needs to be combined with environmental control and allergen avoidance to maintain long-term effects.

VI. Research Progress and Future Prospects of Lokivetmab

In recent years, research on its mechanism of action has continued to deepen. In vitro studies have found that it not only blocks the binding of IL-31 to receptors but also enhances anti-inflammatory effects by clearing free IL-31 through Fc-mediated opsonization. Single-cell sequencing has shown that it can reduce the proportion of IL-31-positive T cells and mast cells in skin and decrease the formation of inflammatory microenvironment, providing a theoretical basis for optimizing drug design.

Structural biology has analyzed the crystal structure of the Lokivetmab-canine IL-31 complex, identifying key binding sites and providing references for the design of human IL-31 monoclonal antibodies. Based on this, analogs with higher affinity and longer half-life have shown better pharmacokinetics and efficacy in preclinical studies.

Future research will explore its application potential in other animal species. Preliminary results show effectiveness in feline allergic skin diseases, but dosage and frequency need adjustment. In equine atopic dermatitis models, IL-31 is involved in pruritus, suggesting its cross-species application value, but targeted preclinical studies are required. Combination therapy is a research hotspot; combined use with JAK inhibitors and IL-4 receptor antagonists may synergistically enhance efficacy and reduce dosage and adverse reactions. Its application in non-allergic pruritic diseases is also being explored.

Lokivetmab has promoted the research and development of targeted biological agents in veterinary medicine, laying the foundation for precise pet medical care. In the future, monoclonal antibodies targeting inflammatory factors such as IL-4 and IL-13 will enter clinical practice, and the development of long-acting sustained-release and oral formulations will improve convenience. With the improvement of pet medical standards and increasing owner attention, the application of targeted biological agents will become more widespread. Its research and development experience provides valuable references for other veterinary biological agents, and future multidisciplinary collaboration and technological innovation will enable veterinary targeted drugs to play an increasingly important role in improving pet health and quality of life.

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next